Common Stock, par value $0.007 per share
- Symbol
- BIAF
- Exchange
- NASDAQ
- Classification
- COMMON
- Status
- Current
Current Report · Items 8.01, 9.01 · 8-K
bioAffinity Technologies, Inc.
BIAFNASDAQEQUITYCurrent
Other Events
Item 8.01. Other Events. On October 6, 2026, bioAffinity Technologies, Inc., a Delaware corporation (the “Company”), issued a press release announcing that sales of its CyPath® Lung test for lung cancer increased more than 100% through the third quarter of 2026 compared to 2025, reflecting continued growth in clinical adoption of the Company’s noninvasive test for assessing the likelihood of lung…
Press release in this filing
bioAffinity Technologies Reports Over 100% Growth in CyPath® Lung Sales Through Third Quarter 2026 →Company context
bioAffinity Technologies, Inc. addresses the need for non-invasive diagnosis of early-stage cancer and other diseases of the lung and broad-spectrum cancer treatments. The Company’s first product, CyPath ® Lung, is a non-invasive test that has shown high sensitivity, specificity and accuracy for the detection of early-stage lung cancer. CyPath® Lung is marketed as a Laboratory Developed Test (LDT) by Precision Pathology Laboratory Services, a subsidiary of bioAffinity Technologies. For more information, visit www.bioaffinitytech.com.
Current securities
Registered securities in this filing
bioAffinity Technologies, Inc. · 8-K · Filed 2026-10-06
Warrants to purchase Common Stock
- Symbol
- BIAFW
- Exchange
- NASDAQ
- Classification
- WARRANT
- Status
- Current
Disclosure sections
Item 8.01Item 8.01 - Other Events
Item
8.01. Other Events.
On
October 6, 2026, bioAffinity Technologies, Inc., a Delaware corporation (the “Company”), issued a press release announcing
that sales of its CyPath® Lung test for lung cancer increased more than 100% through the third quarter of 2026 compared to 2025,
reflecting continued growth in clinical adoption of the Company’s noninvasive test for assessing the likelihood of lung cancer
in high-risk individuals.
A
copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
Filed exhibits (1)
Exhibit 99.1 News Release bioAffinity Technologies Reports Over 100% Growth in CyPath® Lung Sales Through Third Quarter 2026 Nearly 90% increase in number of physician offices using CyPath Lung Utilization expands as physicians who ordered CyPath Lung in 2025 increase usage by nearly 50% SAN ANTONIO, TEXAS - October 6, 2026 - bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company developing noninvasive healthcare solutions for the early detection and monitoring of lung disease, today announced that sales of its CyPath® Lung test for lung cancer increased more than 100% through the third quarter of 2026 compared to 2025, reflecting continued growth in clinical adoption of the Company’s noninvasive test for assessing the likelihood of lung cancer in high-risk individuals. The number of ordering physicians increased by 89% in Q3 2026 compared to Q3 2025. Physicians who ordered CyPath Lung through Q3 2025 continued to expand utilization of the test, with sales volume increasing by 48% year-over-year. Testing through Q3 2026 resulted in more than 1620 tests delivered as compared to 775 tests through Q3 2025. “One of our objectives for 2026 is executing …
Open exhibit ↗